tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

ARQT Stock Latest News

Arcutis Biotherapeutics announces new Zoryve data at EADV congress
The FlyArcutis Biotherapeutics announces new Zoryve data at EADV congress
4d ago
ARQT
Arcutis Biotherapeutics sybmits sNDA for ZORYVE Cream 0.3%
PremiumThe Fly
Arcutis Biotherapeutics sybmits sNDA for ZORYVE Cream 0.3%
17d ago
ARQT
Arcutis Biotherapeutics’ Earnings Call: Growth Amid Challenges
PremiumCompany Announcements
Arcutis Biotherapeutics’ Earnings Call: Growth Amid Challenges
1M ago
ARQT
Arcutis Biotherapeutics price target raised to $25 from $20 at TD Cowen
PremiumThe Fly
Arcutis Biotherapeutics price target raised to $25 from $20 at TD Cowen
1M ago
ARQT
Arcutis Biotherapeutics: Promising Growth Driven by Zoryve’s Success and Strategic Initiatives
PremiumRatings
Arcutis Biotherapeutics: Promising Growth Driven by Zoryve’s Success and Strategic Initiatives
1M ago
ARQT
Arcutis Biotherapeutics price target raised to $22 from $19 at H.C. Wainwright
PremiumThe FlyArcutis Biotherapeutics price target raised to $22 from $19 at H.C. Wainwright
1M ago
ARQT
Arcutis Biotherapeutics Reports Strong Q2 2025 Growth
Premium
Company Announcements
Arcutis Biotherapeutics Reports Strong Q2 2025 Growth
1M ago
ARQT
Arcutis Biotherapeutics: Strong Performance and Growth Potential Drive Buy Rating
Premium
Ratings
Arcutis Biotherapeutics: Strong Performance and Growth Potential Drive Buy Rating
1M ago
ARQT
Arcutis Biotherapeutics reports Q2 EPS (13c), consensus (16c)
PremiumThe Fly
Arcutis Biotherapeutics reports Q2 EPS (13c), consensus (16c)
2M ago
ARQT
Carvana upgraded, Ulta Beauty downgraded: Wall Street’s top analyst calls
PremiumThe Fly
Carvana upgraded, Ulta Beauty downgraded: Wall Street’s top analyst calls
2M ago
EL
FL
Arcutis Biotherapeutics initiated with a Neutral at Goldman Sachs
PremiumThe Fly
Arcutis Biotherapeutics initiated with a Neutral at Goldman Sachs
2M ago
ARQT
Arcutis Biotherapeutics Completes Promising Psoriasis Treatment Study
PremiumCompany Announcements
Arcutis Biotherapeutics Completes Promising Psoriasis Treatment Study
2M ago
ARQT
Arcutis Biotherapeutics assumed with an Overweight at Morgan Stanley
PremiumThe FlyArcutis Biotherapeutics assumed with an Overweight at Morgan Stanley
3M ago
ARQT
Arcutis announces ZORYVE cream receives strong recommendation from AAD
Premium
The Fly
Arcutis announces ZORYVE cream receives strong recommendation from AAD
3M ago
ARQT
Arcutis Biotherapeutics Approves Key Proposals at Annual Meeting
Premium
Company Announcements
Arcutis Biotherapeutics Approves Key Proposals at Annual Meeting
3M ago
8K
ARQT
Arcutis Biotherapeutics enrolls first child in INTEGUMENT-INFANT
PremiumThe Fly
Arcutis Biotherapeutics enrolls first child in INTEGUMENT-INFANT
3M ago
ARQT
Arcutis Biotherapeutics presents new long-term results of ZORYVE cream
PremiumThe Fly
Arcutis Biotherapeutics presents new long-term results of ZORYVE cream
4M ago
ARQT
Buy Rating for Arcutis Biotherapeutics Driven by FDA Approval and Market Potential of Zoryve Foam
PremiumRatings
Buy Rating for Arcutis Biotherapeutics Driven by FDA Approval and Market Potential of Zoryve Foam
4M ago
ARQT
Arcutis Biotherapeutics: Buy Rating Affirmed on FDA Approval and Promising Commercial Prospects for Zoryve Foam
PremiumRatings
Arcutis Biotherapeutics: Buy Rating Affirmed on FDA Approval and Promising Commercial Prospects for Zoryve Foam
4M ago
ARQT
Arcutis Biotherapeutics: Buy Rating Affirmed on Strong FDA Approvals and Promising Pipeline
PremiumRatingsArcutis Biotherapeutics: Buy Rating Affirmed on Strong FDA Approvals and Promising Pipeline
4M ago
ARQT
Arcutis Biotherapeutics reports FDA approves sNDA for Zoryve topical foam
Premium
The Fly
Arcutis Biotherapeutics reports FDA approves sNDA for Zoryve topical foam
4M ago
ARQT
Arcutis announces publication of Genital Psoriasis Wellness Consortium statement
Premium
The Fly
Arcutis announces publication of Genital Psoriasis Wellness Consortium statement
4M ago
ARQT

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >